This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Drug Repurposing: A More Efficient Approach to Drug Development?
Webinars, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Market Insights
Nasal Vaccination: Promises and Challenges
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions
Aptar Pharma discusses how digital solutions improve patient outcomes
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
Aptar Pharma discusses trends and benefits of nasal drug delivery
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
